Novo Nordisk receives positive opinion from the European regulatory authorities for Saxenda(r) (liraglutide 3 mg) for the treatment of obesity


BAGSVAERD, Denmark, Jan. 22, 2015 (GLOBE NEWSWIRE) -- Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a positive opinion for the use of Saxenda® (liraglutide 3 mg) for the treatment of obesity.

Saxenda®, the intended brand name of liraglutide 3 mg, is a once-daily glucagon-like peptide-1 (GLP-1) analogue, with 97% homology to naturally occurring human GLP-1, a hormone involved in appetite regulation.The CHMP positive opinion recommends that Saxenda® will be indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of >= 30 kg/m2 (obese), or >= 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.

For further information

Media:    
Mike Rulis +45 3079 3573 mike@novonordisk.com
Ken Inchausti (US) +1 609 514 8316 kiau@novonordisk.com
Investors:    
Kasper Roseeuw Poulsen +45 3079 4303 krop@novonordisk.com
Jannick Lindegaard Denholt +45 3079 8519 jlis@novonordisk.com
Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com
Daniel Bohsen +45 3079 6376 dabo@novonordisk.com
Frank Daniel Mersebach (US) +1 609 235 8567 fdni@novonordisk.com
     

Company announcement No 4 / 2015

Company announcement No 4 / 2015 http://hugin.info/2013/R/1889013/668577.pdf

HUG#1889013